Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
How I treat relapsed or refractory AML
Susan DeWolf, Martin S. Tallman
*
*
Corresponding author for this work
Medicine, Hematology Oncology Division
Research output
:
Contribution to journal
›
Article
›
peer-review
83
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'How I treat relapsed or refractory AML'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Relapsed or Refractory Acute Myeloid Leukemia
100%
New Agents
66%
Clinical Trials
33%
Chemotherapy
33%
Acute Myeloid Leukemia
33%
New Targets
33%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
33%
Treatment Options
33%
New Therapeutics
33%
Hematologist
33%
5-year Survival
33%
Remission
33%
Resistance Mechanisms
33%
Treatment Paradigms
33%
Site-directed mutation
33%
Disease Biology
33%
Armamentarium
33%
Overall Survival Rate
33%
Illustrative Case
33%
Intensive Chemotherapy
33%
Second Complete Remission
33%
Therapeutic Landscapes
33%
Computational Drug Discovery
33%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Chemotherapy
50%
Remission
50%
Clinical Study
25%
Clinical Trial
25%
Drug Discovery
25%
Overall Survival
25%
Survival Rate
25%
Disease
25%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Chemotherapy
50%
Diseases
25%
Overall Survival
25%
Survival Rate
25%
Hematopoietic Cell
25%
Cell Transplantation
25%
Clinical Study
25%
Clinical Trial
25%